NCT01344018 · REGISTRY CONDITION SEARCH

Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: NA
Status at capture: COMPLETED
Registry last update: 2023-04-24

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known whether surgery is more effective with or without radiation therapy in treating nonmetastatic retroperitoneal soft tissue sarcoma. PURPOSE: This randomized phase III trial is studying radiation therapy followed by surgery to see how well it works compared with surgery alone in treating patients with previously untreated nonmetastatic retroperitoneal soft tissue sarcoma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Patients With Abdominal Recurrence or Death

→

outcome · POSTED

Acute Toxicity Profile of Preoperative Radiotherapy.

→

outcome · POSTED

Perioperative Complications

→

outcome · POSTED

Late Complications

→

outcome · POSTED

Tumor Response to Preoperative Radiotherapy

→

outcome · POSTED

Number of Patients With an Abdominal Recurrence

→

outcome · POSTED

Number of Patients With Metastases or Death

→

outcome · POSTED

Number of Patients Alive

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: DISEASE CHARACTERISTICS: * Histologically confirmed retroperitoneal sarcoma (RPS) by local pathologist, imaging-guided or surgical biopsy, including the following: * Primary soft tissue sarcoma of retroperitoneal space or infra-peritoneal spaces of pelvis * Sarcoma not originated from bone structure, abdominal, or gynecological viscera * Unifocal tumor (not multifocal disease) * Absence of extension through the sciatic notch or across the diaphragm * The following histological sub-types are not allowed: * Gastrointestinal stromal tumor (GIST) * Rhabdomyosarcomas * Primitive neuroectodermal tumor (PNET) or other small round blue cells sarcoma * Osteosarcoma or chondrosarcoma * Aggressive fibromatosis * Sarcomatoid or metastatic carcinoma * No metastatic disease * Untreated disease * Tumor must be operable and suitable for radiotherapy, based on the following criteria: * Pre-treatment CT scan/MRI and multidisciplinary consultation with surgeon, radiation oncologist, and radiologist (anticipated macroscopically complete resection, R0/R1 resection) * No surgery anticipated to be R2 on the CT scan before randomization * Must have American Society of Anesthesiologist (ASA) score ≤ 2 * None of the following unresectable criteria: * Involvement of superior mesenteric artery * Involvement of aorta * Involvement of bone * Must have radiologically measurable disease (RECIST 1.1), as confirmed by abdomino-pelvic CT (with IV and PO contrast) or MRI (with IV contrast) PATIENT CHARACTERISTICS: * WHO performance status 0-2 * WBC ≥ 2,500/mm\^3 * Platelet count ≥ 80,000/mm\^3 * Total bilirubin \< 1.5 times the upper limit normal * Calculated creatinine clearance normal * Functional contra-lateral kidney to the side involved by the RPS as assessed by intravenous pyelogram * Adequate cardiac function (NYHA class I-II) * ECG normal (without clinically significant abnormalities) * No history of any of the following disorders: * Bowel obstruction * Mesenteric ischemia * Severe chronic inflammatory bowel disease * Negative pregnancy test * Not pregnant or nursing concurrently and for at least 1 month after the surgery * Fertile patients must use effective contraception during the study treatment period and for at least 1 month after the surgery * No co-existing malignancy within the past 5 years, except for adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix * No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule PRIOR CONCURRENT THERAPY: * No prior surgery (excluding diagnosis biopsy), radiotherapy, or systemic therapy * No prior abdominal or pelvic irradiation for another prior malignancy or other disease * No concurrent systemic anticancer treatment (chemotherapy, molecular-targeted therapy) * No postoperative radiotherapy planned
healthy Volunteers: false
maximum Age: 120 Years
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
En-bloc resection of surrounding tissues and organs when located within 1 to 2 cm from the surface tumor, even when not infiltrated.
intervention Names
Procedure: therapeutic conventional surgery
label
Surgery alone
type
ACTIVE_COMPARATOR
description
3D-CRT or IMRT to a dose of 50.4 Gy/28 daily fractions
intervention Names
Procedure: therapeutic conventional surgery
Radiation: 3-dimensional conformal radiation therapy
label
Preoperative radiotherapy followed by en-bloc surgery
type
EXPERIMENTAL

interventions

arm Group Labels
Preoperative radiotherapy followed by en-bloc surgery
Surgery alone
name
therapeutic conventional surgery
type
PROCEDURE
arm Group Labels
Preoperative radiotherapy followed by en-bloc surgery
name
3-dimensional conformal radiation therapy
type
RADIATION

Study design

allocation

RANDOMIZED

intervention Model

PARALLEL

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 266
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Abdominal recurrence was defined by one of the following events: local/abdominal or distant progressive disease during preoperative radiotherapy (as per RECIST 1.1), tumor or patient becoming inoperable (ASA score of 3 or involvement of superior mesenteric artery, aorta, or bone), peritoneal metastasis found at surgery, macroscopic residual disease left in at surgery (R2 resection), or local relapse (after macroscopically complete resection). Liver metastases were regarded as distant metastatic events. Patients with distant metastases were followed until local failure was detected. Patients without one of these events were censored at the date of last follow-up.
measure
Number of Patients With Abdominal Recurrence or Death
time Frame
ARFS was measured from date of randomization to date of abdominal relapse or death, whichever occurred first, up to a maximum of 7 years.

secondary Outcomes

description
The acute toxicity was assessed in randomized patients who received at least one dose of preoperative radiotherapy (RT). It follows Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 in the RT safety population, assuming the following classification: * Grade 0 No event reported * Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. * Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL. * Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. * Grade 4 Life-threatening consequences; urgent intervention indicated. * Grade 5 Death related to AE. For each item of the CTCAE, the worst grade of acute toxicity from the data of randomization prior to surgery was taken
measure
Acute Toxicity Profile of Preoperative Radiotherapy.
time Frame
From date of randomization to the date of surgical procedure, prior to surgery
description
Adverse events and side effects possibly related to surgery were assessed according to the Dindo's classification. This scales the observed side effects as Grade 0 No event Grade I Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions Grade II Requiring pharmacological treatment with drugs other than such allowed for grade I complications. Grade III Requiring surgical, endoscopic or radiological intervention Grade IV Life-threatening complication (including CNS complications) requiring IC/ICU-management Grade V Death of a patient For each item, the frequency of the worst grade of the observed toxicity was tabulated by treatment group. The perioperative period commence at the time of surgery (at the time of the induction anaesthesia) to the complete closure of the wound.
measure
Perioperative Complications
time Frame
From the date of surgery, up to 60 days following surgery
description
The late toxicities occurring more than 60 days after surgery. These were reported using Common Terminology Criteria for Adverse Events (CTCAE) v4.0. This scales the observed toxicity from Grade 1 to 5, assuming the following classification: * Grade 0 no event * Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. * Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL. * Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. * Grade 4 Life-threatening consequences; urgent intervention indicated. * Grade 5 Death related to AE. Full AE reporting can be found in the Adverse Event Section.
measure
Late Complications
time Frame
From day 60 after surgery till end of follow-up, up to 7 years
description
For patients that received preoperative radiotherapy, the tumor response was assessed using RECIST 1.1. Response criteria were essentially based on a set of measurable lesions identified at baseline as target lesions, and followed at the end of the radiotherapy. Response was not the primary endpoint, so a confirmatory CT-scan was not mandatory.
measure
Tumor Response to Preoperative Radiotherapy
time Frame
Two weeks after completion of Pre-operative Radiotherapy, before Surgery
description
Abdominal recurrence was defined in the ARFS section. The following are considered competing events: * death in the absence of abdominal failure * distant metastases diagnosed before abdominal failure Patients without one of these events were censored at the date of last follow-up.
measure
Number of Patients With an Abdominal Recurrence
time Frame
ARFI was measured from the date of randomization to the date of abdominal relapse, up to a maximum of 7 years
description
Alive and metastases free patients will be censored at the date of last follow-up.
measure
Number of Patients With Metastases or Death
time Frame
Metastases free survival was measured from the date of randomization to the date of occurrence of distant metastases or death, whichever occurred first, up to a maximum of 7 years.
description
Alive patients were censored at the date of last follow-up. Causes of death were recorded and reported as a table.
measure
Number of Patients Alive
time Frame
Overall survival was measured from the date of randomization to the date of death, whatever the cause, up to a maximum of 7 years

Full study description

brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known whether surgery is more effective with or without radiation therapy in treating nonmetastatic retroperitoneal soft tissue sarcoma. PURPOSE: This randomized phase III trial is studying radiation therapy followed by surgery to see how well it works compared with surgery alone in treating patients with previously untreated nonmetastatic retroperitoneal soft tissue sarcoma.
detailed Description: OBJECTIVES: Primary * To assess whether there is a difference in abdominal recurrence-free survival between retroperitoneal soft tissue sarcoma patients undergoing curative intent surgery alone and those undergoing preoperative radiotherapy followed by curative-intent surgery. Secondary * To assess whether there is a difference in metastasis-free survival, abdominal recurrence-free interval, and overall survival between these patients. * To assess tumor response in patients undergoing preoperative radiotherapy. * To assess toxicity of preoperative radiotherapy given prior to curative-intent surgery in these patients. OUTLINE: This is a multicenter study. Patients are stratified according to institution and WHO performance status (0-1 vs 2). Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients undergo surgical resection of the tumor mass within 4 weeks following randomization. * Arm II: Patients undergo 3-dimensional conformal radiation therapy (RT) or intensity-modulated RT within 8 weeks after randomization. RT continues 5 days a week for approximately 5.5 weeks. Patients undergo surgical resection of the tumor mass within 4-8 weeks after the completion of RT. Tumor tissue, normal abdominal wall fat, and peripheral blood may be collected during surgery to identify new prognostic factors for translational research. After completion of study therapy, patients are followed at day 60 post-surgery and every 6 months thereafter.

Source references

references

citation
Bonvalot S, Gronchi A, Le Pechoux C, Swallow CJ, Strauss D, Meeus P, van Coevorden F, Stoldt S, Stoeckle E, Rutkowski P, Rastrelli M, Raut CP, Hompes D, De Paoli A, Sangalli C, Honore C, Chung P, Miah A, Blay JY, Fiore M, Stelmes JJ, Dei Tos AP, Baldini EH, Litiere S, Marreaud S, Gelderblom H, Haas RL. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020 Oct;21(10):1366-1377. doi: 10.1016/S1470-2045(20)30446-0. Epub 2020 Sep 14.
pmid
32941794
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-80addba1bd52ad785160
requested nct id
NCT01344018
primary nct id
NCT01344018
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Histiocytoma&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
bac1ec1281373ee4e9e39781fe34b553efe52105d6d2ce39d01500a3a6db7b66
payload sha256
b1a49f1cdc5cb67013d0366310f99e48f218c7b1d03ca20d6ff98d941fee0fc1
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-80addba1bd52ad785160
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01344018
occurrences
context exact
NCT01344018
end
11
exact text
NCT01344018
start
0
offset unit
unicode_code_points
query cond
Histiocytoma
query disease state id
ds-histiocytoma
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-histiocytoma-000.json
source file sha256
bac1ec1281373ee4e9e39781fe34b553efe52105d6d2ce39d01500a3a6db7b66
source json pointer
/studies/12/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
47ba3a0a9e48f701ac40edf4aa92df3defdfa6ae5ee153db9c21462e4c6c2e6e
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Histiocytoma&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice